Dean Harvey Speaks on Predatory California Bail Bonds Litigation at California Public Defenders Association Seminar

Dean Harvey Speaks on Predatory California Bail Bonds Litigation at California Public Defenders Association Seminar

Lieff Cabraser partner Dean M. Harvey will be speaking at the California Public Defenders Association (CPDA) “New Statutes” seminar taking place on March 29, 2019 at the Hilton Garden Inn in Emeryville, California. Dean’s talk is titled, “The Newly-Filed Lawsuit Challenging Unfairly High Non-Refundable Premiums Charged for Bail Bonds.” [Read more…]

Dean Harvey to Speak on the Latest Developments in No-Poach Agreements at the California Lawyers Association (CLA)

DMH to Speak at CLA No Poach Program

Lieff Cabraser partner Dean M. Harvey will be featured as a distinguished speaker at the “Latest Developments in No-Poach Agreements” program taking place at the California Lawyers Association (CLA) on January 29, 2019 from 12:00pm,-1:00pm. The program is being put together by the Antitrust, UCL & Privacy Section and the Labor & Employment Section of the CLA and will feature the following: [Read more…]

Dean Harvey to Speak on Anticompetitive Practices in the Labor Market at Harvard Law School

Dean Harvey to Speak on Anticompetitive Practices in the Labor Market at Harvard Law School

Lieff Cabraser partner Dean M. Harvey will be featured as a distinguished speaker at the “Unrigging the Market: Convening to Restore Competitive Labor Markets” program, taking place at Harvard Law School on June 13, 2018 from 8:30am-4:30pm ET. He will be participating in the panel titled “Anticompetitive Practices in the Labor Market.” [Read more…]

Dean Harvey to Speak at 19th Annual American Antitrust Institute Conference, “Antitrust at a Crossroads”

Dean Harvey to Speak at 19th Annual American Antitrust Institute Conference

On June 21, 2018, Lieff Cabraser partner Dean M. Harvey will participate as a panelist at the 19th annual American Antitrust Institute conference, “Antitrust at a Crossroads – Plotting the Course for the Next Decade” at the National Press Club in Washington, D.C. Dean will speak on “Antitrust and Workers — Agreements, Mergers, and Monopsony,” exploring applications of the antitrust laws to prohibit the exercise of buyer power that harms competition and suppresses wages and salaries. [Read more…]

Dean Harvey and Lin Chan Featured at BASF Antitrust for HR Seminar

Lieff Cabraser Attorneys Featured at BASF Antitrust for HR Seminar

Lieff Cabraser attorneys Lin Y. Chan and Dean M. Harvey spoke at the Bar Association of San Francisco’s Antitrust for HR: No-Poach and Wage Fixing Agreements seminar on January 16, 2018. Ms. Chan moderated the panel, and Mr. Harvey participated in the discussion. [Read more…]

American Bar Association Names Dean Harvey a 2017 On the Rise – Top 40 Young Lawyer

American Bar Association Names Dean Harvey a 2017 On the Rise – Top 40 Young Lawyer

Lieff Cabraser partner Dean M. Harvey has been recognized as a 2017 American Bar Association (ABA) On the Rise – Top 40 Young Lawyer. The ABA notes the award is a testament to Mr. Harvey’s superb legal reputation in the industry and his service toward the public good. The ABA’s profile of Dean references his work as a leader in the High-Tech Antitrust case against Google, Apple, and other tech giants for allegedly conspiring to suppress mobility and compensation of their technical employees, citing the case as the most significant antitrust employment case in recent history, widely recognized as a legal and public policy breakthrough. [Read more…]

Dean Harvey Comments on Valeant-Kadmon Pharma Antitrust Challenges

Dean Harvey Comments on Valeant-Kadmon Pharma Antitrust Challenges

Reuters has published a compelling analysis of ongoing challenges facing pharmaceutical “rogue” Valeant with a focus on its price-inflated drug Syprine and its relationship with also-beleagured pharma company Kadmon. Among other issues, Valeant has been singled out as a prime offender in the realm of hyper-inflated pharmaceutical drugs, with, Syprine, its life-saving Wilson’s disease liver ailment treatment costing some patients nearly $300,000 for a year’s use (in 2011, Valeant priced the drug at less than $1,000 for 100 capsules, a rate that rose by 2015 to over $21,000 for the same dose). [Read more…]